Robyn M. Busch

Robyn M. Busch

Auto-generated profile, based on publicly available information

Robyn M. Busch

Epilepsy Center Neurological Institute, Cleveland Clinic Cleveland Ohio USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2022 in Epilepsia
Verified
Journal Article
Closed access
LJLara Jehi
Lara Jehi
NJNathalie Jette
Nathalie Jette
CKChurl-Su Kwon
Churl-Su Kwon
CJColin B. Josephson
Colin B. Josephson
JBJorge G. Burneo
Jorge G. Burneo
SWSamuel Wiebe
Samuel Wiebe

14 October 2021 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LJLara Jehi
Lara Jehi
MMMarcia Morita‐Sherman
Marcia Morita‐Sherman
TLThomas E. Love
Thomas E. Love
FBFabrice Bartolomei
Fabrice Bartolomei
WBWilliam Bingaman
William Bingaman
SWSamuel Wiebe
Samuel Wiebe

1 August 2014 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JRJaivir S. Rathore
Jaivir S. Rathore
LJLara E. Jehi
Lara E. Jehi
YFYouran Fan
Youran Fan
SPSima I. Patel
Sima I. Patel
NFNancy Foldvary-Schaefer
Nancy Foldvary-Schaefer
GTGeorge E. Tesar
George E. Tesar

5 May 2021 in Epilepsia
Verified
Journal Article
Open access
PDF file
IBIngmar Blumcke
Ingmar Blumcke
RCRoland Coras
Roland Coras
RBRobyn M. Busch
Robyn M. Busch
MMMarcia Morita‐Sherman
Marcia Morita‐Sherman
DLDennis Lal
Dennis Lal
INImad Najm
Imad Najm
Objective: Focal cortical dysplasia (FCD) is a major cause of difficult‐to‐treat epilepsy in children and young adults, and the diagnosis is currently based on microscopic review of surgical brain tissue using the International League Against Epilepsy classification scheme of 2011. We developed an iterative histopathological agreement trial with genetic testing to identify areas of diagnostic challenges in this widely used classification scheme.Methods: Four web‐based digital pathology trials were completed by 20 neuropathologists from 15 countries using a consecutive series of 196 surgical tissue blocks obtained from 22 epilepsy patients at a single center. Five independent genetic laboratories performed screening or validation sequencing of FCD‐relevant genes in paired brain and blood samples from the same 22 epilepsy patients.Results: Histopathology agreement based solely on hematoxylin and eosin stainings was low in Round 1, and gradually increased by adding a panel of immunostainings in Round 2 and the Delphi consensus method in Round 3. Interobserver agreement was good in Round 4 (kappa = .65), when the results of genetic tests were disclosed, namely, MTOR, AKT3, and SLC35A2 brain somatic mutations in five cases and germline mutations in DEPDC5 and NPRL3 in two cases.Significance: The diagnoses of FCD 1 and 3 subtypes remained most challenging and were often difficult to differentiate from a normal homotypic or heterotypic cortical architecture. Immunohistochemistry was helpful, however, to confirm the diagnosis of FCD or no lesion. We observed a genotype–phenotype association for brain somatic mutations in SLC35A2 in two cases with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy. Our results suggest that the current FCD classification should recognize a panel of immunohistochemical stainings for a better histopathological workup and definition of FCD subtypes. We also propose adding the level of genetic findings to obtain a comprehensive, reliable, and integrative genotype–phenotype diagnosis in the near future.

13 October 2022 in Brain
Verified
Journal Article
Open access
PDF file
JLJavier A López-Rivera
Javier A López-Rivera
CLCostin Leu
Costin Leu
MMMarie Macnee
Marie Macnee
JKJean Khoury
Jean Khoury
LHLucas Hoffmann
Lucas Hoffmann
DLDennis Lal
Dennis Lal
Understanding the exact molecular mechanisms involved in the aetiology of epileptogenic pathologies with or without tumour activity is essential for improving treatment of drug-resistant focal epilepsy. Here, we characterize the landscape of somatic genetic variants in resected brain specimens from 474 individuals with drug-resistant focal epilepsy using deep whole-exome sequencing (>350×) and whole-genome genotyping. Across the exome, we observe a greater number of somatic single-nucleotide variants in low-grade epilepsy-associated tumours (7.92 ± 5.65 single-nucleotide variants) than in brain tissue from malformations of cortical development (6.11 ± 4 single-nucleotide variants) or hippocampal sclerosis (5.1 ± 3.04 single-nucleotide variants). Tumour tissues also had the largest number of likely pathogenic variant carrying cells. low-grade epilepsy-associated tumours had the highest proportion of samples with one or more somatic copy-number variants (24.7%), followed by malformations of cortical development (5.4%) and hippocampal sclerosis (4.1%). Recurring somatic whole chromosome duplications affecting Chromosome 7 (16.8%), chromosome 5 (10.9%), and chromosome 20 (9.9%) were observed among low-grade epilepsy-associated tumours. For germline variant-associated malformations of cortical development genes such as TSC2, DEPDC5 and PTEN, germline single-nucleotide variants were frequently identified within large loss of heterozygosity regions, supporting the recently proposed ‘second hit’ disease mechanism in these genes. We detect somatic variants in 12 established lesional epilepsy genes and demonstrate exome-wide statistical support for three of these in the aetiology of low-grade epilepsy-associated tumours (e.g. BRAF) and malformations of cortical development (e.g. SLC35A2 and MTOR). We also identify novel significant associations for PTPN11 with low-grade epilepsy-associated tumours and NRAS Q61 mutated protein with a complex malformation of cortical development characterized by polymicrogyria and nodular heterotopia. The variants identified in NRAS are known from cancer studies to lead to hyperactivation of NRAS, which can be targeted pharmacologically. We identify large recurrent 1q21–q44 duplication including AKT3 in association with focal cortical dysplasia type 2a with hyaline astrocytic inclusions, another rare and possibly under-recognized brain lesion. The clinical-genetic analyses showed that the numbers of somatic single-nucleotide variant across the exome and the fraction of affected cells were positively correlated with the age at seizure onset and surgery in individuals with low-grade epilepsy-associated tumours. In summary, our comprehensive genetic screen sheds light on the genome-scale landscape of genetic variants in epileptic brain lesions, informs the design of gene panels for clinical diagnostic screening and guides future directions for clinical implementation of epilepsy surgery genetics.

10 December 2022 in Psychiatry Research
Verified
Journal Article
Closed access
Jordi A. Matias-GuiuJordi A. Matias-Guiu
Jordi A. Matias-Guiu
EHElena Herrera
Elena Herrera
MGMaría González-Nosti
María González-Nosti
KKKamini Krishnan
Kamini Krishnan
CDCristina Delgado-Alonso
Cristina Delgado-Alonso
BHBruce P Hermann
Bruce P Hermann